Stay updated with breaking news from Stephan Weidinger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and...
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD sh...
Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Patients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Area and
BALLERUP, Denmark, October 11, 2023--Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial